{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:17:01Z","timestamp":1788790621897,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["18181MFDS403"],"award-info":[{"award-number":["18181MFDS403"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016275","name":"Seoul National University Bundang Hospital","doi-asserted-by":"publisher","award":["13-2018-012"],"award-info":[{"award-number":["13-2018-012"]}],"id":[{"id":"10.13039\/100016275","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To investigate pharmacokinetic and pharmacodynamic differences of zolpidem between males and females and their causes, including CYP3A4 activity. A single oral dose of zolpidem (10\u00a0mg) was administered to 15 male and 15 female healthy subjects. Blood samples were collected up to 12\u00a0h post-dose to determine plasma zolpidem concentrations. Pharmacokinetic parameters were obtained using non-compartmental analysis. Digit symbol substitution test, choice reaction time, and visual analog scale of sleepiness were used to evaluate pharmacodynamics. We measured CYP3A4 activity using 4\u03b2-hydroxycholesterol, an endogenous metabolite. Mean maximum plasma concentration and area under the plasma concentration\u2013time curve were higher for females than for males (9.9% and 32.5%, respectively); other pharmacokinetic parameters showed no significant differences. Pharmacodynamic scores for females showed delayed recovery compared with that for males. CYP3A4 activity was higher in females than in males (<jats:italic>p<\/jats:italic>\u2009=\u20090.030). There was no serious adverse event, and adverse event incidence was not different between the sexes. Zolpidem exposure was about 30% higher in females than in males. Delayed pharmacodynamic score recovery in females could be related to higher zolpidem concentrations. Although apparent clearance was lower in females, systemic clearance might not be the cause of the different exposures to zolpidem.<\/jats:p>","DOI":"10.1038\/s41598-021-98689-z","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T10:20:00Z","timestamp":1632738000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Effect of CYP3A4 metabolism on sex differences in the pharmacokinetics and pharmacodynamics of zolpidem"],"prefix":"10.1038","volume":"11","author":[{"given":"Seonghae","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongmee","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eben","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Soon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inseung","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo-Youn","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo-Yong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Yong","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"key":"98689_CR1","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/jamainternmed.2018.3031","volume":"178","author":"TJ Moore","year":"2018","unstructured":"Moore, T. J. & Mattison, D. R. Assessment of patterns of potentially unsafe use of zolpidem. JAMA Intern. Med. 178, 1275\u20131277. https:\/\/doi.org\/10.1001\/jamainternmed.2018.3031 (2018).","journal-title":"JAMA Intern. Med."},{"key":"98689_CR2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1001\/jamainternmed.2016.7507","volume":"177","author":"TJ Moore","year":"2017","unstructured":"Moore, T. J. & Mattison, D. R. Adult utilization of psychiatric drugs and differences by sex, age, and race. JAMA Intern. Med. 177, 274\u2013275. https:\/\/doi.org\/10.1001\/jamainternmed.2016.7507 (2017).","journal-title":"JAMA Intern. Med."},{"key":"98689_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00127-018-1615-x","volume":"54","author":"MH Lee","year":"2019","unstructured":"Lee, M. H. et al. Trends in prescriptions for sedative-hypnotics among Korean adults: A nationwide prescription database study for 2011\u20132015. Soc. Psychiatry Psychiatr. Epidemiol. 54, 477\u2013484. https:\/\/doi.org\/10.1007\/s00127-018-1615-x (2019).","journal-title":"Soc. Psychiatry Psychiatr. Epidemiol."},{"key":"98689_CR4","unstructured":"Nocdurna (desmopressin acetate) [package insert]. Parsippany: Ferring Pharmaceuticals Inc.; 2018."},{"key":"98689_CR5","doi-asserted-by":"publisher","first-page":"F1116","DOI":"10.1152\/ajprenal.00741.2010","volume":"300","author":"KV Juul","year":"2011","unstructured":"Juul, K. V., Klein, B. M., Sandstrom, R., Erichsen, L. & Norgaard, J. P. Gender difference in antidiuretic response to desmopressin. Am. J. Physiol. Renal Physiol. 300, F1116-1122. https:\/\/doi.org\/10.1152\/ajprenal.00741.2010 (2011).","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"98689_CR6","unstructured":"BELSOMRA (suvorexant) [package insert] Whitehouse Station: Merck & Co., Inc.; 2014."},{"key":"98689_CR7","unstructured":"U.S. Food and Drug Administration. Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). http:\/\/wayback.archive-it.org\/7993\/20170111080036\/http:\/www.fda.gov\/Drugs\/DrugSafety\/ucm334033.htm (2013)"},{"key":"98689_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/JCP.0000000000001026","volume":"39","author":"DJ Greenblatt","year":"2019","unstructured":"Greenblatt, D. J., Harmatz, J. S. & Roth, T. Zolpidem and gender: Are women really at risk?. J. Clin. Psychopharmacol. 39, 189\u2013199. https:\/\/doi.org\/10.1097\/JCP.0000000000001026 (2019).","journal-title":"J. Clin. Psychopharmacol."},{"key":"98689_CR9","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMp1307972","volume":"369","author":"RH Farkas","year":"2013","unstructured":"Farkas, R. H., Unger, E. F. & Temple, R. Zolpidem and driving impairment\u2013identifying persons at risk. N. Engl. J. Med. 369, 689\u2013691. https:\/\/doi.org\/10.1056\/NEJMp1307972 (2013).","journal-title":"N. Engl. J. Med."},{"key":"98689_CR10","unstructured":"AMBIEN (zolpidem tartrate) [package insert]. Bridgewater: Sanofi-aventis; 2019."},{"key":"98689_CR11","unstructured":"Handok, Inc. Stilnox (zolpidem tartrate) [package insert] Korean Ministry of Food and Administration. https:\/\/nedrug.mfds.go.kr\/pbp\/CCBBB01\/getItemDetail?itemSeq=200700634"},{"key":"98689_CR12","unstructured":"Pharmacovigilance Risk Assessment Committee (PRAC) EMA. Assessement report for zolpidem-containing medicinal products. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/zolpidem-article-31-referral-prac-assessment-report_en.pdf"},{"key":"98689_CR13","first-page":"435","volume":"293","author":"DJ Greenblatt","year":"2000","unstructured":"Greenblatt, D. J. et al. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: Evaluation of sex-dependent differences. J. Pharmacol. Exp. Ther. 293, 435\u2013443 (2000).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"98689_CR14","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.clinthera.2013.03.007","volume":"35","author":"DJ Greenblatt","year":"2013","unstructured":"Greenblatt, D. J. et al. Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: Results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. Clin. Ther. 35, 604\u2013611. https:\/\/doi.org\/10.1016\/j.clinthera.2013.03.007 (2013).","journal-title":"Clin. Ther."},{"key":"98689_CR15","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/jcph.220","volume":"54","author":"DJ Greenblatt","year":"2014","unstructured":"Greenblatt, D. J. et al. Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration. J. Clin. Pharmacol. 54, 282\u2013290. https:\/\/doi.org\/10.1002\/jcph.220 (2014).","journal-title":"J. Clin. Pharmacol."},{"key":"98689_CR16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1046\/j.0306-5251.2003.01852.x","volume":"56","author":"JO Olubodun","year":"2003","unstructured":"Olubodun, J. O. et al. Pharmacokinetic properties of zolpidem in elderly and young adults: Possible modulation by testosterone in men. Br. J. Clin. Pharmacol. 56, 297\u2013304. https:\/\/doi.org\/10.1046\/j.0306-5251.2003.01852.x (2003).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"98689_CR17","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.apsb.2014.02.001","volume":"4","author":"T Guo","year":"2014","unstructured":"Guo, T., Mao, G., Zhao, L., Xia, D. & Yang, L. Comparative pharmacokinetics of zolpidem tartrate in five ethnic populations of China. Acta Pharm. Sin. B 4, 146\u2013150. https:\/\/doi.org\/10.1016\/j.apsb.2014.02.001 (2014).","journal-title":"Acta Pharm. Sin. B"},{"key":"98689_CR18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s40266-014-0211-3","volume":"31","author":"DJ Greenblatt","year":"2014","unstructured":"Greenblatt, D. J. et al. Pharmacokinetics of zolpidem from sublingual zolpidem tartrate tablets in healthy elderly versus non-elderly subjects. Drugs Aging 31, 731\u2013736. https:\/\/doi.org\/10.1007\/s40266-014-0211-3 (2014).","journal-title":"Drugs Aging"},{"key":"98689_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.2165\/00003088-199529030-00002","volume":"29","author":"P Salva","year":"1995","unstructured":"Salva, P. & Costa, J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin. Pharmacokinet. 29, 142\u2013153. https:\/\/doi.org\/10.2165\/00003088-199529030-00002 (1995).","journal-title":"Clin. Pharmacokinet."},{"key":"98689_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1046\/j.1365-2125.1999.00953.x","volume":"48","author":"LL Von Moltke","year":"1999","unstructured":"Von Moltke, L. L. et al. Zolpidem metabolism in vitro: Responsible cytochromes, chemical inhibitors, and in vivo correlations. Br. J. Clin. Pharmacol. 48, 89\u201397. https:\/\/doi.org\/10.1046\/j.1365-2125.1999.00953.x (1999).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"98689_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2165\/00003495-199040020-00008","volume":"40","author":"HD Langtry","year":"1990","unstructured":"Langtry, H. D. & Benfield, P. Z. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 40, 291\u2013313. https:\/\/doi.org\/10.2165\/00003495-199040020-00008 (1990).","journal-title":"Drugs"},{"key":"98689_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1124\/mol.109.056705","volume":"76","author":"DJ Waxman","year":"2009","unstructured":"Waxman, D. J. & Holloway, M. G. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol. Pharmacol. 76, 215\u2013228. https:\/\/doi.org\/10.1124\/mol.109.056705 (2009).","journal-title":"Mol. Pharmacol."},{"key":"98689_CR23","doi-asserted-by":"publisher","first-page":"1000119","DOI":"10.4172\/2157-7609.1000119","volume":"3","author":"L Yang","year":"2012","unstructured":"Yang, L. et al. Sex Differences in the expression of drug-metabolizing and transporter genes in human liver. J. Drug Metab. Toxicol. 3, 1000119. https:\/\/doi.org\/10.4172\/2157-7609.1000119 (2012).","journal-title":"J. Drug Metab. Toxicol."},{"key":"98689_CR24","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1053\/jhep.2003.50393","volume":"38","author":"R Wolbold","year":"2003","unstructured":"Wolbold, R. et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38, 978\u2013988. https:\/\/doi.org\/10.1053\/jhep.2003.50393 (2003).","journal-title":"Hepatology"},{"key":"98689_CR25","unstructured":"R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/."},{"key":"98689_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.12793\/tcp.2020.28.e10","volume":"28","author":"Y Lee","year":"2020","unstructured":"Lee, Y., Chae, W., Yoon, S., Chung, J. Y. & Cho, J. Y. Development and validation of a method for the simultaneous quantification of endogenous steroids metabolized by CYP3A. Transl. Clin. Pharmacol 28, 73\u201382. https:\/\/doi.org\/10.12793\/tcp.2020.28.e10 (2020).","journal-title":"Transl. Clin. Pharmacol"},{"key":"98689_CR27","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/JCP.0000000000000941","volume":"38","author":"J Jaeger","year":"2018","unstructured":"Jaeger, J. Digit symbol substitution test: The case for sensitivity over specificity in neuropsychological testing. J. Clin. Psychopharmacol. 38, 513\u2013519. https:\/\/doi.org\/10.1097\/JCP.0000000000000941 (2018).","journal-title":"J. Clin. Psychopharmacol."},{"key":"98689_CR28","doi-asserted-by":"publisher","first-page":"e0221802","DOI":"10.1371\/journal.pone.0221802","volume":"14","author":"J Kim","year":"2019","unstructured":"Kim, J., Gabriel, U. & Gygax, P. Testing the effectiveness of the Internet-based instrument PsyToolkit: A comparison between web-based (PsyToolkit) and lab-based (E-Prime 3.0) measurements of response choice and response time in a complex psycholinguistic task. PLoS ONE 14, e0221802. https:\/\/doi.org\/10.1371\/journal.pone.0221802 (2019).","journal-title":"PLoS ONE"},{"key":"98689_CR29","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3758\/BRM.42.4.1096","volume":"42","author":"G Stoet","year":"2010","unstructured":"Stoet, G. PsyToolkit: A software package for programming psychological experiments using Linux. Behav. Res. Methods 42, 1096\u20131104. https:\/\/doi.org\/10.3758\/BRM.42.4.1096 (2010).","journal-title":"Behav. Res. Methods"},{"issue":"10","key":"98689_CR30","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/oxfordjournals.aje.a009937","volume":"150","author":"A Paul-Dauphin","year":"1999","unstructured":"Paul-Dauphin, A., Guillemin, F., Virion, J. M. & Briancon, S. Bias and precision in visual analogue scales: A randomized controlled trial. Am. J. Epidemiol. 150(10), 1117\u20131127 (1999).","journal-title":"Am. J. Epidemiol."},{"key":"98689_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/03602532.2016.1239630","volume":"49","author":"J Mao","year":"2017","unstructured":"Mao, J. et al. Perspective: 4beta-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A. Drug Metab. Rev. 49, 18\u201334. https:\/\/doi.org\/10.1080\/03602532.2016.1239630 (2017).","journal-title":"Drug Metab. Rev."},{"key":"98689_CR32","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/bcp.12707","volume":"80","author":"AJ de Graan","year":"2015","unstructured":"de Graan, A. J. et al. 4beta-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. Br. J. Clin. Pharmacol. 80, 560\u2013568. https:\/\/doi.org\/10.1111\/bcp.12707 (2015).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"98689_CR33","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/bcp.12425","volume":"78","author":"S Kasichayanula","year":"2014","unstructured":"Kasichayanula, S. et al. Validation of 4beta-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. Br. J. Clin. Pharmacol. 78, 1122\u20131134. https:\/\/doi.org\/10.1111\/bcp.12425 (2014).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"98689_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2125.2010.03773.x","volume":"71","author":"U Diczfalusy","year":"2011","unstructured":"Diczfalusy, U., Nylen, H., Elander, P. & Bertilsson, L. 4beta-hydroxycholesterol, an endogenous marker of CYP3A4\/5 activity in humans. Br. J. Clin. Pharmacol. 71, 183\u2013189. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03773.x (2011).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"98689_CR35","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/cpt.1472","volume":"106","author":"S Gravel","year":"2019","unstructured":"Gravel, S., Chiasson, J. L., Gaudette, F., Turgeon, J. & Michaud, V. Use of 4beta-hydroxycholesterol plasma concentrations as an endogenous biomarker of CYP3A activity: Clinical validation in individuals with type 2 diabetes. Clin. Pharmacol. Ther. 106, 831\u2013840. https:\/\/doi.org\/10.1002\/cpt.1472 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"key":"98689_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1517\/17425255.4.4.413","volume":"4","author":"MJ Scandlyn","year":"2008","unstructured":"Scandlyn, M. J., Stuart, E. C. & Rosengren, R. J. Sex-specific differences in CYP450 isoforms in humans. Exp. Opin. Drug Metab. Toxicol. 4, 413\u2013424. https:\/\/doi.org\/10.1517\/17425255.4.4.413 (2008).","journal-title":"Exp. Opin. Drug Metab. Toxicol."},{"issue":"11","key":"98689_CR37","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1177\/0269881109106898","volume":"24","author":"SL de Haas","year":"2010","unstructured":"de Haas, S. L. et al. Pharmacokinetics, pharmacodynamics and the pharmacokinetic\/pharmacodynamic relationship of zolpidem in healthy subjects. J. Psychopharmacol. 24(11), 1619\u20131629 (2010).","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"98689_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/026988119901300102","volume":"13","author":"AL van Steveninck","year":"1999","unstructured":"van Steveninck, A. L. et al. The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation. J. Psychopharmacol. 13(1), 10\u201317 (1999).","journal-title":"J. Psychopharmacol."},{"issue":"5","key":"98689_CR39","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/jcph.1391","volume":"59","author":"SR Penzak","year":"2019","unstructured":"Penzak, S. R. & Rojas-Fernandez, C. 4beta-hydroxycholesterol as an endogenous biomarker for CYP3A activity: Literature review and critical evaluation. J. Clin. Pharmacol. 59(5), 611\u2013624 (2019).","journal-title":"J. Clin. Pharmacol."},{"issue":"2","key":"98689_CR40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/clpt.2009.72","volume":"86","author":"D Tomalik-Scharte","year":"2009","unstructured":"Tomalik-Scharte, D. et al. Plasma 4beta-hydroxycholesterol: An endogenous CYP3A metric?. Clin. Pharmacol. Ther. 86(2), 147\u2013153 (2009).","journal-title":"Clin. Pharmacol. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98689-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98689-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98689-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:14:54Z","timestamp":1670084094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98689-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["98689"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-98689-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,27]]},"assertion":[{"value":"9 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ki Soon Kim, Seongmee Jeong, Eben Jung, Woo-Yong Oh, and Jehyuk Chung are employees of the Ministry of Food and Drug Safety. None of the other authors have any conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19150"}}